文献速递消化、代谢与肾脏急症

美国2006至2017年各州阿片类药物处方实践的地理差异趋势与模式

Trends and Patterns of Geographic Variation in Opioid Prescribing Practices by State, United States, 2006-2017.
PubMed 文献 · JAMA Netw Open · 2019-03-01
一句话结论2006至2017年美国阿片处方人均总量下降12.8%,但平均处方时长增加37.6%至17.9天,各州措施差异达2至3倍。

该研究基于IQVIA Xponent数据库,对2006年1月1日至2017年12月31日全美零售药房配发的阿片类药物处方进行基于人群的横断面分析,纳入所有在美国零售药房配发阿片处方的美国居民。结果显示,人均阿片处方量从628.4 MME降至543.4 MME(平均下降12.8%),高日剂量(≥90 MME)、短期(≤3天)处方及缓释和长效制剂处方率均下降;但平均处方时长从13.0天增至17.9天(平均增加37.6%),30天及以上处方率从18.3/100人增至24.9/100人(平均增加37.7%)。按各州第90与第10百分位比值衡量,多数州在5项措施上存在2至3倍地理差异。作者认为该信息可能有助于设计州特异性干预项目。

要点

  • 2006至2017年全美每年约配发2.337亿张阿片处方,人均阿片处方量从628.4 MME降至543.4 MME,平均下降12.8%,但仅在23个州达统计学显著。
  • 高日剂量(≥90 MME)处方率从12.3/100人降至5.6/100人,平均下降53.1%,在49个州达统计学显著。
  • 短期(≤3天)处方率从18.0/100人降至10.0/100人,平均下降43.1%,在48个州达统计学显著。
  • 平均处方时长从13.0天增至17.9天,平均增加37.6%,在每个州均达统计学显著;30天及以上处方率从18.3/100人增至24.9/100人,平均增加37.7%,在39个州达统计学显著。
  • 缓释和长效制剂处方率从7.2/100人降至6.0/100人,平均下降14.7%,在27个州达统计学显著;按各州第90与第10百分位比值衡量,多数州在5项措施上存在2至3倍地理差异。

适用人群与场景

  • 所有在美国零售药房配发阿片类处方的美国居民。
  • 数据来源为IQVIA Xponent数据库,覆盖全美零售药房。

诊断标准与关键阈值

  • 高日剂量定义为每日剂量≥90 MME。
  • 短期处方定义为疗程≤3天。
  • 长期处方定义为疗程≥30天。
  • 缓释和长效制剂为独立处方措施。

研究设计与关键结果

  • 研究类型为基于人群的横断面分析,数据时间范围为2006年1月1日至2017年12月31日。
  • 2006至2017年全美零售药房每年估计配发2.337亿张阿片处方。
  • 人均阿片处方量从628.4(178.0)MME降至543.4(158.6)MME,平均(SD)下降12.8%(12.6%),在23个州达统计学显著。
  • 高日剂量(≥90 MME)处方率从12.3(3.4)/100人降至5.6(1.7)/100人,平均(SD)下降53.1%(13.6%),在49个州达统计学显著。
  • 短期(≤3天)处方率从18.0(5.4)/100人降至10.0(2.5)/100人,平均(SD)下降43.1%(9.4%),在48个州达统计学显著。
  • 缓释和长效制剂处方率从7.2(1.9)/100人降至6.0(1.7)/100人,平均(SD)下降14.7%(13.7%),在27个州达统计学显著。
  • 平均处方时长从13.0(1.2)天增至17.9(1.4)天,平均(SD)增加37.6%(6.9%),在每个州均达统计学显著。
  • 30天及以上处方率从18.3(7.7)/100人增至24.9(10.7)/100人,平均(SD)增加37.7%(28.9%),在39个州达统计学显著。按各州第90与第10百分位比值衡量,多数州在5项措施上存在2至3倍地理差异。

证据类型、等级与局限

  • 证据类型为基于人群的横断面分析。
  • 作者指出部分下降达统计学显著,但结果仍高;作者认为该信息可能有助于设计州特异性干预项目。

对床旁实践的改变

  • 作者认为该信息可能有助于设计州特异性干预项目。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Risk of opioid use disorder, overdose, and death from prescription opioids increases as dosage, duration, and use of extended-release and long-acting formulations increase. States are well suited to respond to the opioid crisis through legislation, regulations, enforcement, surveillance, and other interventions.

OBJECTIVE: To estimate temporal trends and geographic variations in 6 key opioid prescribing measures in 50 US states and the District of Columbia.

DESIGN, SETTING, AND PARTICIPANTS: Population-based cross-sectional analysis of opioid prescriptions filled nationwide at US retail pharmacies between January 1, 2006, and December 31, 2017. Data were obtained from the IQVIA Xponent database. All US residents who had an opioid prescription filled at a US retail pharmacy were included.

MAIN OUTCOMES AND MEASURES: Primary outcomes were annual amount of opioids prescribed in morphine milligram equivalents (MME) per person; mean duration per prescription in days; and 4 separate prescribing rates-for prescriptions 3 or fewer days, those 30 days or longer, those with a high daily dosage (≥90 MME), and those with extended-release and long-acting formulations.

RESULTS: Between 2006 and 2017, an estimated 233.7 million opioid prescriptions were filled in retail pharmacies in the United States each year. For all states combined, 4 measures decreased: (1) mean (SD) amount of opioids prescribed (mean [SD] decrease, 12.8% [12.6%]) from 628.4 (178.0) to 543.4 (158.6) MME per person, a statistically significant decrease in 23 states; (2) high daily dosage (mean [SD] decrease, 53.1% [13.6%]) from 12.3 (3.4) to 5.6 (1.7) per 100 persons, a statistically significant decrease in 49 states; (3) short-term (≤3 days) duration (mean [SD] decrease, 43.1% [9.4%]) from 18.0 (5.4) to 10.0 (2.5) per 100 persons, a statistically significant decrease in 48 states; and (4) extended-release and long-acting formulations (mean [SD] decrease, 14.7% [13.7%]) from 7.2 (1.9) to 6.0 (1.7) per 100 persons, a statistically significant decrease in 27 states. Two measures increased, each associated with the duration of prescription dispensed: (1) mean (SD) prescription duration (mean [SD] increase, 37.6% [6.9%]) from 13.0 (1.2) to 17.9 (1.4) days, a statistically significant increase in every state; and (2) prescriptions for a term of 30 days or longer (mean [SD] increase, 37.7% [28.9%]) from 18.3 (7.7) to 24.9 (10.7) per 100 persons, a statistically significant increase in 39 states. Two- to 3-fold geographic differences were observed across states, measured by comparing the ratio of each state's 90th to 10th percentile for each measure.

CONCLUSIONS AND RELEVANCE: In this study, across 12 years, the mean duration and prescribing rate for long-term prescriptions of opioids increased, whereas the amount of opioids prescribed per person and prescribing rate for high-dosage prescriptions, short-term prescriptions, and extended-release and long-acting formulations decreased. Some decreases were significant, but results were still high. Two- to 3-fold state variation in 5 measures occurred in most states. This information may help when state-specific intervention programs are being designed.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Schieber LZ, Guy GP, Seth P, et al. Trends and Patterns of Geographic Variation in Opioid Prescribing Practices by State, United States, 2006-2017. JAMA Netw Open. 2019. PMID: 30874783. doi:10.1001/jamanetworkopen.2019.0665

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。